Premarket Alert: Synovus Financial (NYSE: SNV
Synovus Financial (NYSE: SNV) shares are down about 3% in premarket trading on active early volume after Fitch Ratings downgraded the bank’s long and short-term issuer default ratings with a negative outlook. The ratings agency cited significant exposure to troubled regions of the Southeast, and credit concerns stemming from residential construction, development, and land loan [...]
Premarket Alert: China Architectural Engineering (CAEI)
China Architectural Engineering Inc. (Nasdaq: CAEI) are among the most active premarket small caps, up about 30% after the company announced a new contract worth more than $500 million to build a Shanghai resort. The company has reached an agreement with Shanghai Nine Dragon Co. for major projects within the Nine Dragon Resort, Zhejiang, including [...]
PreMarket Alert: IMAX Corp. (IMAX)
IMAX Corp. (NASDAQ: IMAX) shares are up about 10% in premarket trading after the company announced that Roth Capital, the underwriter of its recent stock offering, has exercised an option to buy 1.47 million common shares at $7.15 a share, as part of an over-allotment option.
Volume Alert: Insmed may be active after Phase II trial result (INSM)
Insmed Inc. (Nasdaq: INSM) announced this morning that its IPLEX candidate for treating muscular dystrophy did not show a statistically significant improvement in the functional measure of endurance in a Phase II trial. Shares were halted just before 8 a.m. Eastern this morning, pending the announcement.
Price/Volume Alert: First Solar (FSLR)
Shares of First Solar, Inc. (NASDAQ: FSLR) are getting hit to the downside this morning. Because there is still almost two hours until the open and because most NASDAQ quotes are still off screen the volume is still very light. But shares are indicated down almost $4.00 from the $171.19 close on Wednesday. Canaccord Adams [...]
Premarket Alert: Jazz Pharma and fibromyalgia plays may be active today (JAZZ)
Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) shares are up more than 30% on strong premarket volume and may be one of the most active biotech stocks today after the fibromyalgia treatment developer said preliminary data from a second Phase III trial of its pain drug Xyrem met its primary endpoint. The company in a press release said 573 patients treated [...]
VS Investor RSS Feed